Skip to main content
SpringerLink
Log in
Book cover

Progress in Colorectal Surgery pp 59–92Cite as

Advances in the Medical Treatment of Crohn’s Disease

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16.

    Google Scholar 

  2. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut 1994;35:1433–1438.

    PubMed  CAS  Google Scholar 

  3. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol. 1992; 27:609–614.

    PubMed  CAS  Google Scholar 

  4. Cosgrove M, Al-Atia RF, Jenkins HR. The epidemiology of paediatric inflammatory bowel disease. Arch Dis Child. 1996;74:460–461.

    Article  PubMed  CAS  Google Scholar 

  5. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2001;3:CD000301.

    Google Scholar 

  6. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45–51.

    Article  PubMed  CAS  Google Scholar 

  7. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–845.

    Article  PubMed  CAS  Google Scholar 

  8. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut 2001;48:186–90.

    Article  PubMed  CAS  Google Scholar 

  9. Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr. 2001;33:75–80.

    Article  PubMed  CAS  Google Scholar 

  10. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2001;1:CD002913.

    Google Scholar 

  11. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370–374.

    Article  PubMed  CAS  Google Scholar 

  12. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology 2002;123:33–40.

    Article  PubMed  CAS  Google Scholar 

  13. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–987.

    Article  PubMed  CAS  Google Scholar 

  14. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci. 1985;30:58–64.

    PubMed  CAS  Google Scholar 

  15. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990;99:1347–1351.

    PubMed  CAS  Google Scholar 

  16. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:CD000545.

    Google Scholar 

  17. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:CD000067.

    Google Scholar 

  18. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895–902.

    Article  PubMed  CAS  Google Scholar 

  19. Cuillerier E, Lemann M, Bouhnik Y, Allez M, Rambaud JC, Modigliani R. Azathioprine for prevention of postoperative recurrence in Crohn’s disease: a retrospective study. Eur J Gastroenterol Hepatol. 2001; 13:1291–1296.

    Article  PubMed  CAS  Google Scholar 

  20. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, doubleblind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med. 1989;321:845–850.

    Article  PubMed  CAS  Google Scholar 

  21. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR. European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. The European Study Group. Gastroenterology 1995;109: 774–782.

    Article  PubMed  CAS  Google Scholar 

  22. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease.The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med. 1994;330:1846–1851.

    Article  PubMed  CAS  Google Scholar 

  23. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000;118: 264–273.

    PubMed  CAS  Google Scholar 

  24. Korelitz B, Hanauer S, Rutgeerts P, et al. Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn’s disease: A 2 year multicenter trial. Gastroenterology 1998;114:A1011.

    Google Scholar 

  25. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145–153.

    Article  PubMed  CAS  Google Scholar 

  26. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383–387.

    PubMed  CAS  Google Scholar 

  27. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–1075.

    PubMed  CAS  Google Scholar 

  28. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328–332.

    PubMed  CAS  Google Scholar 

  29. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.

    Article  PubMed  CAS  Google Scholar 

  30. Rutgeerts P, Van Assche G, D’Haens G, et al. Ornidazol for prophylaxis of postoperative Crohn’s disease: final results of a double blind placebo controlled trial. Gastroenterology 2002; 122:A–135.

    Google Scholar 

  31. Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn’s disease tissue. Gut 1992;33:890–896.

    PubMed  CAS  Google Scholar 

  32. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Twoyear-outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother. 1997; 39: 393–400.

    Article  PubMed  CAS  Google Scholar 

  33. Thomas GA, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study. Gut 1998;42:497–500.

    Article  PubMed  CAS  Google Scholar 

  34. Stokkers PC, Camoglio L, van Deventer SJ. Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. J Inflamm. 1995-1996;47:97–103.

    PubMed  CAS  Google Scholar 

  35. Cominelli F. Tumor necrosis factor modulation: from bench to bedside. Inflamm Bowel Dis. 2000; 6:S21–S22.

    Google Scholar 

  36. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  37. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439–444.

    PubMed  CAS  Google Scholar 

  38. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–769.

    Article  PubMed  CAS  Google Scholar 

  39. Hanauer SB, Feagan BG, Lichtenstein GR, et al, for the ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.

    Article  PubMed  CAS  Google Scholar 

  40. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  41. D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999;116:1029–1034.

    PubMed  CAS  Google Scholar 

  42. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122:1592–1608.

    Article  PubMed  CAS  Google Scholar 

  43. Farrell R, Alsahli M, Falchuk K, Peppercorn M, Michetti P. Human antichimeric antibody levels correlate with lack of efficacy and infusion reactions following infliximab therapy. Gastroenterology 2001;120: A–69.

    Google Scholar 

  44. Norman M, Baert F, D’Haens G, et al. HACA formation after infliximab (Remicade) treatment in Crohn’s disease is clearly associated with infusion reactions. Gastroenterology 2001;120: A261.

    Google Scholar 

  45. Farrell R, Alsahli M, Falchuk K, Peppercorn M, Michetti P. A randomised, double-blind placebo-controlled trial of intravenous hydrocrtisone in reducing human anti-chimeric antibody formation following infliximab therapy. Gastroenterology 2001;120:A618–619.

    Google Scholar 

  46. Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2–4 year interval without treatment. Gastrenterology. 1999;116:A731.

    Google Scholar 

  47. Vermeire S, Norman M, Van Assche G, et al. Infliximab (Remicade) treatment in Crohn’s disease and antinuclear antibody (ANA) formation. Gastroenterology 2001;120:A–69.

    Google Scholar 

  48. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–155.

    PubMed  CAS  Google Scholar 

  49. Salmon-Ceron D. Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris). 2002;153:429–431.

    CAS  Google Scholar 

  50. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46: 3151–3158.

    Article  PubMed  CAS  Google Scholar 

  51. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997;349:521–524.

    Article  PubMed  CAS  Google Scholar 

  52. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120: 1330–1338.

    Article  PubMed  CAS  Google Scholar 

  53. Feagan BG, Sandborn WJ, Baker J, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn’s disease. Gastroenterology 2000;118:A655.

    Google Scholar 

  54. D’Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial. Am J Gastroenterol. 2001;96:2564–2568.

    PubMed  CAS  Google Scholar 

  55. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–1094.

    Article  PubMed  CAS  Google Scholar 

  56. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185–192.

    PubMed  CAS  Google Scholar 

  57. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148–1157.

    PubMed  CAS  Google Scholar 

  58. Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr. 2001;32:178–181.

    PubMed  CAS  Google Scholar 

  59. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 1999;117:1278–1287.

    PubMed  CAS  Google Scholar 

  60. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999;117:1271–1277.

    PubMed  CAS  Google Scholar 

  61. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185–201.

    Article  PubMed  CAS  Google Scholar 

  62. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 2002;122:7–14.

    Article  PubMed  CAS  Google Scholar 

  63. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997;113:383–389.

    PubMed  Google Scholar 

  64. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119:1461–1472.

    Article  PubMed  CAS  Google Scholar 

  65. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473–1482.

    Article  PubMed  CAS  Google Scholar 

  66. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352–1355.

    Article  PubMed  CAS  Google Scholar 

  67. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281–1290.

    Article  PubMed  CAS  Google Scholar 

  68. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996;26:934–938.

    PubMed  CAS  Google Scholar 

  69. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Antiinterleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078–1088.

    Article  PubMed  CAS  Google Scholar 

  70. Debinski H, Forbes A, Kamm MA. Low dose interferon gamma for refractory Crohn’s disease. Ital J Gastroenterol Hepatol. 1997;29:403–406.

    PubMed  CAS  Google Scholar 

  71. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol. 2001;281: R1264–R1267.

    PubMed  CAS  Google Scholar 

  72. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003;98:369–376.

    PubMed  Google Scholar 

  73. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 1998;114:1133–1142.

    Article  PubMed  CAS  Google Scholar 

  74. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology 2001;120:1339–1346.

    Article  PubMed  CAS  Google Scholar 

  75. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut 2002;51:30–36.

    Article  PubMed  CAS  Google Scholar 

  76. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1761–1770.

    Article  PubMed  CAS  Google Scholar 

  77. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348:24–32.

    Article  PubMed  CAS  Google Scholar 

  78. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 2001;121:268–274.

    Article  PubMed  CAS  Google Scholar 

  79. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16: 699–705.

    Article  PubMed  CAS  Google Scholar 

  80. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373–1380.

    Article  PubMed  CAS  Google Scholar 

  81. Feagan B, McDonald J, Greenberg G, et al. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology 2000;118:A874.

    Article  Google Scholar 

  82. James SP. Remission of Crohn’s disease after human immunodeficiency virus infection. Gastroenterology 1988;95:1667–1669.

    PubMed  CAS  Google Scholar 

  83. Emmrich J, Seyfarth M, Fleig WE, et al. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991;338:570–571.

    Article  PubMed  CAS  Google Scholar 

  84. Canva-Delcambre V, Jacquot S, Robinet E, et al. Treatment of severe Crohn’s disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther. 1996; 10:721–727.

    Article  PubMed  CAS  Google Scholar 

  85. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn’s disease. N Engl J Med. 1999;340:239–240.

    Article  PubMed  CAS  Google Scholar 

  86. Korzenik J, Dieckgraefe B. Immunostimulation in Crohn’s disease: results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn’s disease. Gastroenterology 2000;118:A874.

    Google Scholar 

  87. Korzenik J, Dieckgraefe B. Immunostimulation in Crohn’s disease: safety and efficacy of rhuGM-CSF for the treatment of active Crohn’s disease. Gastroenterology 2001;120:A277–A287.

    Google Scholar 

  88. Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1:27–39.

    PubMed  CAS  Google Scholar 

  89. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD000957.

    Google Scholar 

  90. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110: 353–356.

    PubMed  CAS  Google Scholar 

  91. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–297.

    Article  PubMed  CAS  Google Scholar 

  92. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  93. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724–1729.

    PubMed  CAS  Google Scholar 

  94. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 1999; 13:1597–1604.

    Article  PubMed  CAS  Google Scholar 

  95. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn’s disease: a double-blind, randomised, Israeli multicenter trial. Am J Gastroenterol. 1997;92:2203–2209.

    PubMed  CAS  Google Scholar 

  96. Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther. 1996;10:309–314.

    PubMed  CAS  Google Scholar 

  97. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J Pediatr. 132:830–835.

    Google Scholar 

  98. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–3156.

    Article  PubMed  CAS  Google Scholar 

  99. Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment PharmacolTher. 1997;11:569–573.

    CAS  Google Scholar 

  100. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988;95:1523–1527.

    PubMed  CAS  Google Scholar 

  101. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373–380.

    Article  PubMed  CAS  Google Scholar 

  102. Katschinski B, Logan RF, Edmond M, Langman MJ. Smoking and sugar intake are separate but interactive risk factors in Crohn’s disease. Gut 1988;29:1202–1206.

    PubMed  CAS  Google Scholar 

  103. Riordan AM, Ruxton CH, Hunter JO. A review of associations between Crohn’s disease and consumption of sugars. Eur J Clin Nutr. 1998;52:229–238.

    Article  PubMed  CAS  Google Scholar 

  104. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn’s disease. J Parenter Enteral Nutr. 1985;9:280–287.

    Article  CAS  Google Scholar 

  105. Seo M, Okada M, Yao T, Furukawa H, Matake H. The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease. J Clin Gastroenterol. 1999;29:270–275.

    Article  PubMed  CAS  Google Scholar 

  106. Kobayashi K, Katsumata T, Yokoyama K, Takahashi H, Igarashi M, Saigenji K. [A randomized controlled study of total parenteral nutrition and enteral nutrition by elemental and polymeric diet as primary therapy in active phase of Crohn’s disease]. Nippon Shokakibyo Gakkai Zasshi 1998;95:1212–1221.

    PubMed  CAS  Google Scholar 

  107. Teahon K, Pearson M, Levi AJ, Bjarnason I. Elemental diet in the management of Crohn’s disease during pregnancy. Gut 1991;32:1079–1081.

    PubMed  CAS  Google Scholar 

  108. Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn’s disease. Gastroenterology 1991;101:84–89.

    PubMed  CAS  Google Scholar 

  109. O’Morain C, Segal AW, Levi AJ. Elemental diets in treatment of acute Crohn’s disease. Br Med J. 1980;281:1173–1175.

    PubMed  CAS  Google Scholar 

  110. Harries AD, Jones LA, Danis V, et al. Controlled trial of supplemented oral nutrition in Crohn’s disease. Lancet 1983;1:887–890.

    PubMed  CAS  Google Scholar 

  111. O’Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn’s disease: a controlled trial. Br Med J (Clin Res Ed). 1984;288:1859–1862.

    CAS  Google Scholar 

  112. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Results of the European Cooperative Crohn’s Disease Study. IV. Gastroenterology 1991;101:881–888.

    PubMed  CAS  Google Scholar 

  113. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 1995;108:1056–1056.

    Article  PubMed  CAS  Google Scholar 

  114. Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years’ experience with an elemental diet in the management of Crohn’s disease. Gut 1990;31:1133–1137.

    PubMed  CAS  Google Scholar 

  115. Teahon K, Pearson M, Levi AJ, Bjarnason I. Practical aspects of enteral nutrition in the management of Crohn’s disease. J Parenter Enteral Nutr. 1995;19:365–368.

    CAS  Google Scholar 

  116. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8–15.

    Article  PubMed  CAS  Google Scholar 

  117. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol. 2000;95:735–739.

    Article  PubMed  CAS  Google Scholar 

  118. Leiper K, Woolner J, Mullan MM, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn’s disease. Gut 2001;49:790–794.

    Article  PubMed  CAS  Google Scholar 

  119. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut 2002;51:164–168.

    Article  PubMed  CAS  Google Scholar 

  120. Sakurai T, Matsui T, Yao T, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. J Parenter Enteral Nutr. 2002;26:98–103.

    CAS  Google Scholar 

  121. Tsujikawa T, Satoh J, Uda K, et al. Clinical importance of n-3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn’s disease. J Gastroenterol. 2000;35:99–104.

    PubMed  CAS  Google Scholar 

  122. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med. 1996;334:1557–1560.

    Article  PubMed  CAS  Google Scholar 

  123. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebocontrolled trial. Gastroenterology 2000;119:305–309.

    Article  PubMed  CAS  Google Scholar 

  124. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659–664.

    Article  PubMed  CAS  Google Scholar 

  125. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31: 453–457.

    PubMed  CAS  Google Scholar 

  126. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405–409.

    Article  PubMed  CAS  Google Scholar 

  127. Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn’s disease. Eur J Gastroenterol Hepatol. 2001; 13:101–106.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University College Hospitals, The Middlesex Hospital, London, UK

    Sara McCartney MB BS, PhD, MRCP

  2. St George’s Hospital Medical School, London, UK

    Michael J.G. Farthing DSc, MD, FRCP, FmedSci

Authors
  1. Sara McCartney MB BS, PhD, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J.G. Farthing DSc, MD, FRCP, FmedSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Colorectal Surgery, Singleton Hospital, Swansea, UK

    John Beynon BSc, MS, FRCS  & Nicholas D. Carr MD, FRCS  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

McCartney, S., Farthing, M.J. (2005). Advances in the Medical Treatment of Crohn’s Disease. In: Beynon, J., Carr, N.D. (eds) Progress in Colorectal Surgery. Springer, London. https://doi.org/10.1007/1-84628-058-3_4

Download citation

  • DOI: https://doi.org/10.1007/1-84628-058-3_4

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-823-7

  • Online ISBN: 978-1-84628-058-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation